What does this research mean for the field?

Tocilizumab attenuates the inflammatory response and reduces troponin T release in NSTEMI patients compared to placebo. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

May 8, 2016Open Access

Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial

Key Result

Tocilizumab attenuated the inflammatory response and reduced troponin T release in NSTEMI patients compared to placebo.

Structured PICO

Does a single dose of tocilizumab reduce inflammation and troponin T release in patients with NSTEMI?

Population

Patients with non-ST-elevation myocardial infarction (NSTEMI)

Intervention

Single dose of tocilizumab (interleukin-6 receptor antagonist)

Comparator

Placebo

Outcome

Inflammation and troponin T releasesurrogate

A single dose of tocilizumab attenuates inflammation and PCI-related troponin T release in patients with NSTEMI.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

Tocilizumab attenuated the inflammatory response and primarily PCI-related TnT release in NSTEMI patients.

Read Full Paperexternally

Bookmark

View Full Paper

Bookmark

View Full Paper

Cite This Study

Kleveland et al. (Sun,) reported a other. Tocilizumab attenuated the inflammatory response and reduced troponin T release in NSTEMI patients compared to placebo.

synapsesocial.com/papers/696308dd7247ee1819be2f36 https://doi.org/https://doi.org/10.1093/eurheartj/ehw171